Want to see HK:6699 full AI Analyst Report?
Top Page
Angelalign Technology Inc.
(6699)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$86.00
▼(-4.71% Downside)
Action:Upgraded
Date:09/18/26
The score is primarily supported by strong financial quality (very low leverage) and solid cash generation alongside improving operating performance. Technicals are moderately positive with the stock above key long-term moving averages. The main offset is valuation, with a high P/E and limited dividend yield.
Positive Factors
Very low leverage
Extremely low leverage gives Angelalign substantial financial resilience and flexibility. A strong equity base reduces dependence on lenders, limits interest burden, and supports continued investment in products and digital orthodontic capabilities through changing operating conditions.
Negative Factors
Modest profitability
Although operating profitability has improved, the modest net margin shows the company has not restored its earlier earnings efficiency. Lower profitability leaves less room to absorb cost increases or reinvest heavily while maintaining attractive returns for shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Extremely low leverage gives Angelalign substantial financial resilience and flexibility. A strong equity base reduces dependence on lenders, limits interest burden, and supports continued investment in products and digital orthodontic capabilities through changing operating conditions.
Read all positive factors
Angelalign Technology Inc. (6699) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$13.19B
Dividend Yield1.26%
Average Volume (3M)328.52K
Price to Earnings (P/E)39.1
Beta (1Y)0.80
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees4,478
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.66
Shares Outstanding172,335,020
10 Day Avg. Volume348,896
30 Day Avg. Volume328,517
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)2.59
Price to Sales (P/S)3.49
P/FCF Ratio17.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$103.57Price Target Upside14.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.19
Revenue Forecast (FY)HK$482.42M
Angelalign Technology Inc. Business Overview & Revenue Model
Company Description
Angelalign Technology Inc. functions as an investment holding enterprise primarily dedicated to the innovation, production, and distribution of clear aligner solutions for orthodontic treatment throughout China. Their key offerings, Angel Aligner ...
Angelalign Technology Inc. Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
88
Very Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.05B | 2.59B | 1.96B | 1.48B | 1.27B | 1.27B |
| Gross Profit | 1.92B | 1.60B | 1.23B | 920.71M | 785.69M | 826.65M |
| EBITDA | 525.06M | 293.27M | 110.87M | 154.39M | 318.65M | 372.47M |
| Net Income | 283.84M | 199.13M | 88.42M | 53.48M | 213.78M | 285.85M |
Balance Sheet | ||||||
| Total Assets | 5.36B | 5.34B | 4.95B | 4.76B | 4.49B | 4.14B |
| Cash, Cash Equivalents and Short-Term Investments | 2.82B | 3.00B | 436.83M | 3.44B | 3.65B | 3.63B |
| Total Debt | 573.49M | 114.00M | 14.48M | 65.28M | 28.20M | 30.29M |
| Total Liabilities | 2.54B | 1.82B | 1.44B | 1.35B | 884.01M | 826.11M |
| Stockholders Equity | 2.80B | 3.49B | 3.46B | 3.34B | 3.61B | 3.32B |
Cash Flow | ||||||
| Free Cash Flow | 623.98M | 523.39M | -76.78M | 51.28M | 51.48M | 241.95M |
| Operating Cash Flow | 795.13M | 712.07M | 229.79M | 165.87M | 146.87M | 441.71M |
| Investing Cash Flow | 537.07M | -1.26B | -138.82M | -981.71M | -159.77M | -182.05M |
| Financing Cash Flow | -1.00B | -175.45M | -28.46M | -187.06M | -193.61M | 2.52B |
Angelalign Technology Inc. Technical Analysis
Negative
90.25
Price Trends
84.75
Negative
79.84
Negative
73.84
Positive
Market Momentum
-2.05
Positive
34.25
Neutral
25.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6699, the sentiment is Negative. The current price of 90.25 is above the 20-day moving average (MA) of 80.88, above the 50-day MA of 84.75, and above the 200-day MA of 73.84, indicating a neutral trend. The MACD of -2.05 indicates Positive momentum. The RSI at 34.25 is Neutral, neither overbought nor oversold. The STOCH value of 25.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6699.
Angelalign Technology Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$6.79B | 9.96 | 20.11% | 3.99% | 12.50% | 44.44% | |
74 Outperform | HK$13.19B | 39.13 | 8.95% | 1.26% | ― | ― | |
67 Neutral | HK$1.28B | 26.55 | 1.10% | 7.15% | -1.64% | -68.67% | |
61 Neutral | HK$6.34B | 21.57 | 9.64% | 0.87% | 34.94% | 12.99% | |
60 Neutral | HK$14.54B | 9.09 | 5.64% | 5.24% | 7.47% | -26.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6699
Angelalign Technology Inc.
76.55
14.99
24.35%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.22
-2.04
-38.76%
HK:1358
PW Medtech Group Ltd.
0.90
-0.56
-38.36%
HK:3600
Modern Dental Group Limited
7.27
2.19
43.08%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
30.00
0.12
0.39%
Angelalign Technology Inc. Corporate Events
Angelalign Shareholders Approve Three-Year RSU Grants for Directors
Sep 30, 2026
Angelalign Technology Inc., a Hong Kong-listed orthodontic technology company incorporated in the Cayman Islands, provides clear aligner and related dental solutions to patients and practitioners. Its operations are supported by a mix of executive...
Angelalign Calls EGM to Approve Three-Year RSU Grants for Top Executives
Sep 11, 2026
Angelalign Technology Inc. has called an extraordinary general meeting in Shanghai on September 30, 2026, to seek shareholder approval for a series of restricted share unit grants to key executives. The proposed awards include 208,617 RSUs to Chai...
Angelalign Awards RSUs as Global Business Drives Profit Surge
Sep 11, 2026
Angelalign Technology Inc. has approved the grant of 1,563,929 restricted share units under its post-IPO RSU scheme to 16 grantees, including three executive directors and 13 other employees. The grants are designed as both a one-time, three-year ...
Angelalign Announces HKD 4.1 Special Dividend for First Half of 2026
Aug 31, 2026
Angelalign Technology Inc. has announced a special cash dividend of HKD 4.1 per share for the six-month period ended 30 June 2026, payable in Hong Kong dollars with no applicable withholding tax. The ex-dividend date is set for 10 September 2026, ...
Angelalign Declares HKD 0.47 Interim Dividend for First Half of 2026
Aug 31, 2026
Angelalign Technology Inc. has declared an interim ordinary dividend of HKD 0.47 per share for the six-month period ended 30 June 2026, for the financial year ending 31 December 2026. The dividend will be paid in Hong Kong dollars, with an ex-divi...
Angelalign’s Global Growth Drives Profit Surge and Shareholder Payouts
Aug 31, 2026
Angelalign Technology Inc. reported strong interim results for the six months ended 30 June 2026, driven by rapid growth in clear aligner demand. Total case volume rose 40.2% to 316,609, with global markets outside the Chinese mainland contributin...
Angelalign Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 3, 2026
Angelalign Technology Inc. has scheduled a board meeting for August 31, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider the payment o...
Angelalign forecasts sharp profit and revenue gains on aligner demand
Jul 31, 2026
Angelalign Technology Inc. expects a strong interim performance for the six months ended June 30, 2026, with clear aligner case volume rising about 40% to roughly 316,600 and revenue climbing over 40% to around USD229–231 million, while net ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.